Clinical trials: Multiple Primary Neoplasm
Hypertension
CKD-828 Telmisartan Non-Responder Trial
The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately…
- Trial name
- NCT01426100
- Testing
- CKD-828 40/2.5mg, CKD-828 40/5mg, Telmisartan 80mg
- Where
- 18 sites in South Korea
- Volunteers
- 183 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM…
- Trial name
- NCT04405245
- Testing
- Latanoprost ophthalmic solution, AKB-9778 4%
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Migraine
Acute Treatment of Migraine With e-TNS
The main objective of this study is to assess the efficacy of the Cefaly® device as an acute treatment of migraine attack in adult patients.
- Trial name
- ACME (NCT02590939)
- Testing
- CEFALY Active
- Where
- 3 sites in United States
- Volunteers
- 106 people
- Sponsor
- Cefaly Technology
Primary Immune Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
The study is designed to be a randomized, open, multi-center, phase IIa/IIb seamless adaptive trial. Phase IIa: The study consists of a screening period, a core treatment period, an open label extension period, and a safety…
- Trial name
- NCT05232149
- Testing
- Orelabrutinib( lower dose), Orelabrutinib( higher dose)
- Where
- 9 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Hereditary Angioedema (HAE)
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE. Participants will be treated with lanadelumab for 26 weeks.
- Trial name
- NCT05460325
- Testing
- Lanadelumab
- Where
- 4 sites in China
- Volunteers
- 20 people
- Sponsor
- Takeda
Hiv
Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients
A Randomized, Double-Blind, Parallel-Group, Exploratory Clinical Study to Evaluate the Safety, Pharmacodynamic Effects, and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Treatment-Naive…
- Trial name
- NCT06560489
- Testing
- Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
Postoperative Pain
An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy
The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain control in patients undergoing hysterectomy on the basis of pharmacokinetics, efficacy and safety evaluations.
- Trial name
- NCT00993226
- Testing
- SABER-Bupivacaine Treatment 1a, Bupivacaine HCl Treatment 1c, SABER-Bupivacaine Treatment 2a
- Where
- 14 sites in France, Germany and 4 more
- Volunteers
- 115 people
- Sponsor
- Durect
Non-Small Cell Lung Cancer
Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of Asian subjects with unresectable stage III non-small cell lung…
- Trial name
- INSPIRE (NCT01015443)
- Testing
- Tecemotide, Single low dose cyclophosphamide, Saline
- Where
- 47 sites in China, Hong Kong and 3 more
- Volunteers
- 285 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Pain, Postoperative, Hernia, Inguinal
Surgical Pain After Inguinal Hernia Repair (SPAIHR)
The purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following…
- Trial name
- NCT00551135
- Testing
- Pregabalin
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 425 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Heart Disease
Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)
To evaluate the safety and efficacy of MiStent drug (sirolimus)-eluting stent system in the treatment of coronary heart disease (CHD) in patients with primary in situ CHD (de novo); To evaluate operating performance of the…
- Trial name
- DESSOLVE-C (NCT02448524)
- Testing
- MiStent, TIVOLI
- Where
- 16 sites in China
- Volunteers
- 428 people
- Sponsor
- Micell Technologies
Myelofibrosis (MF)
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with Myelofibrosis.
- Trial name
- HEMA-MED (NCT06887803)
- Testing
- Roginolisib
- Where
- 12 sites in Italy, Spain and 1 more
- Volunteers
- 26 people
- Sponsor
- iOnctura
Primary Hypercholesterolemia
Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia
To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in adults with primary hypercholesterolemia; To determine the safety of HS-25 (20mg) in…
- Trial name
- HS-25-III-01 (NCT03413462)
- Testing
- HS-25
- Volunteers
- 374 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Sjögren's Syndrome
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from…
- Trial name
- NCT02843659
- Testing
- BMS-931699, BMS-986142
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Nocturnal Enuresis
A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis
To evaluate the overall response to desmopressin treatment among previously untreated enuretic children aged 5-15 years after 3 and 6 months of treatment.
- Trial name
- DRIP (NCT00245479)
- Testing
- Primary nocturnal enuresis
- Where
- France
- Volunteers
- 802 people, healthy volunteers welcome
- Sponsor
- Ferring Pharmaceuticals
Primary Hyperoxaluria
Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients
The main purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.
- Trial name
- PHOENIX (NCT00638703)
- Testing
- Oxalobacter formigenes
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- OxThera
Locally Recurrent Prostate Cancer
An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy
The purpose of this study is to determine the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
- Trial name
- NCT00686088
- Testing
- PRX302
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sophiris Bio Corp
Infections, Meningococcal
Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
The purpose/aim of this study is to assess the safety and antibody response to vaccination with a booster dose of Menveo given 4-6 years after primary MenACWY vaccination and to assess the safety and antibody response to a single…
- Trial name
- NCT02986854
- Testing
- Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 704 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Osteoarthritis
A Multi-centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Polyethylene-on-metal Bearing in Primary Total Hip Replacement
The purpose of this study is to monitor the performance of the Pinnacle™ Cup with a polyethylene-on-metal bearing combination in the treatment of patients with hip joint disease requiring a total hip replacement.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Collagen Disorders
- Trial name
- NCT00208429
- Testing
- Pinnacle Acetabular System
- Sponsor
- DePuy International
Healthy Volunteers, Sjögren's Syndrome
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
Primary Sjögren's syndrome (pSS) is a condition when the body's immune system attacks glands that produce fluids, such as the tear and saliva glands. This leads to dry eyes and a dry mouth.
- Trial name
- NCT06544642
- Testing
- ASP5502
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Primary Ciliary Dyskinesia
A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
The goal of this observational study is to characterize clinical measures and biomarkers of airway disease in adults with primary ciliary dyskinesia (PCD) and in a group of healthy volunteers (HV) to establish normative values.
- Trial name
- NCT05685186
- Testing
- Spirometry, Multiple Breath Washout (MBW), Mucociliary Clearance (MCC)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- ReCode Therapeutics